國立虎尾科技大學 |

HCV: The Journey from Discovery to a Cure = Volume I /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	HCV: The Journey from Discovery to a Cure/ edited by Michael J. Sofia.
其他題名:	Volume I /
其他作者:	Sofia, Michael J.
面頁冊數:	VIII, 463 p. 1 illus.online resource. :
Contained By:	Springer Nature eBook
標題:	Medicinal chemistry. -
電子資源:	https://doi.org/10.1007/978-3-030-28207-3
ISBN:	9783030282073

HCV: The Journey from Discovery to a Cure = Volume I /
HCV: The Journey from Discovery to a CureVolume I /[electronic resource] :edited by Michael J. Sofia. - 1st ed. 2019. - VIII, 463 p. 1 illus.online resource. - Topics in Medicinal Chemistry,311862-2461 ;. - Topics in Medicinal Chemistry,15.

Identification of the virus, the medical need and clearing the blood supply -- Mapping the HCV genome -- The molecular virology of HCV -- The development of the HCV replicon system -- The Evolution of IFN therapy for HCV -- Evolution of HCV NS5B Non-Nucleoside Inhibitors -- Evolution of HCV NS5B Nucleoside & Nucleotide Inhibitors -- Discovery and Development of Sofosbuvir -- Discovery of Beclabuvir -- Discovery of Dasabuvir -- Evolution of HCV NS3/4 protease inhibitors -- Discovery and Development of Telaprevir -- Discovery and Development of Boceprevir -- Discovery and Development of Asunaprevir.-Discovery and Development of Grazoprevir -- Discovery and Development of Simeprevir -- Discovery and Development of Paritaprevir & Glecaprevir.

Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting antiviral drugs that led to cure rates approaching 100% in all patient populations after only 8-12 weeks of therapy. These efforts resulted in one of the greatest achievements in public health and provides the potential for eliminating HCV as a major disease worldwide. This volume is aimed at a broad audience of academic and industrial scientists interested in the discovery and development of drugs to treat viral diseases and those interested in reading about one of the most unique accomplishments in biomedical research. The volume will provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is the companion book to the volume "HCV: The Journey from Discovery to a Cure - Volume II".

ISBN: 9783030282073

Standard No.: 10.1007/978-3-030-28207-3doiSubjects--Topical Terms:

1253747
Medicinal chemistry.

LC Class. No.: RS400-431

Dewey Class. No.: 615.19

HCV: The Journey from Discovery to a Cure = Volume I /
LDR:03458nam a22004095i 4500 001 1013561
003 DE-He213
005 20200703003732.0
007 cr nn 008mamaa
008 210106s2019 gw | s |||| 0|eng d
020 $a 9783030282073 $9 978-3-030-28207-3
024 7 $a 10.1007/978-3-030-28207-3 $2 doi
035 $a 978-3-030-28207-3
050 4 $a RS400-431
072 7 $a PSB $2 bicssc
072 7 $a SCI013020 $2 bisacsh
072 7 $a PSB $2 thema
082 0 4 $a 615.19 $2 23
245 1 0 $a HCV: The Journey from Discovery to a Cure $h [electronic resource] : $b Volume I / $c edited by Michael J. Sofia.
250 $a 1st ed. 2019.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2019.
300 $a VIII, 463 p. 1 illus. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Topics in Medicinal Chemistry, $x 1862-2461 ; $v 31
505 0 $a Identification of the virus, the medical need and clearing the blood supply -- Mapping the HCV genome -- The molecular virology of HCV -- The development of the HCV replicon system -- The Evolution of IFN therapy for HCV -- Evolution of HCV NS5B Non-Nucleoside Inhibitors -- Evolution of HCV NS5B Nucleoside & Nucleotide Inhibitors -- Discovery and Development of Sofosbuvir -- Discovery of Beclabuvir -- Discovery of Dasabuvir -- Evolution of HCV NS3/4 protease inhibitors -- Discovery and Development of Telaprevir -- Discovery and Development of Boceprevir -- Discovery and Development of Asunaprevir.-Discovery and Development of Grazoprevir -- Discovery and Development of Simeprevir -- Discovery and Development of Paritaprevir & Glecaprevir.
520 $a Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting antiviral drugs that led to cure rates approaching 100% in all patient populations after only 8-12 weeks of therapy. These efforts resulted in one of the greatest achievements in public health and provides the potential for eliminating HCV as a major disease worldwide. This volume is aimed at a broad audience of academic and industrial scientists interested in the discovery and development of drugs to treat viral diseases and those interested in reading about one of the most unique accomplishments in biomedical research. The volume will provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is the companion book to the volume "HCV: The Journey from Discovery to a Cure - Volume II".
650 0 $a Medicinal chemistry. $3 1253747
650 0 $a Virology. $3 644995
650 0 $a Medical biochemistry. $3 1254555
650 0 $a Bioorganic chemistry. $3 743635
650 0 $a Pharmaceutical technology. $3 557391
650 1 4 $a Medicinal Chemistry. $3 668872
650 2 4 $a Medical Biochemistry. $3 668897
650 2 4 $a Bioorganic Chemistry. $3 677511
650 2 4 $a Pharmaceutical Sciences/Technology. $3 768561
700 1 $a Sofia, Michael J. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1303413
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030282066
776 0 8 $i Printed edition: $z 9783030282080
776 0 8 $i Printed edition: $z 9783030282097
830 0 $a Topics in Medicinal Chemistry, $x 1862-2461 ; $v 15 $3 1253746
856 4 0 $u https://doi.org/10.1007/978-3-030-28207-3
912 $a ZDB-2-CMS
912 $a ZDB-2-SXC
950 $a Chemistry and Materials Science (SpringerNature-11644)
950 $a Chemistry and Material Science (R0) (SpringerNature-43709)